# reload+after+2024-01-22 23:47:00.598606
address1§6 Liberty Square
address2§Suite 2382
city§Boston
state§MA
zip§02109
country§United States
phone§857 837 3099
website§https://www.transcodetherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
fullTimeEmployees§19
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert Michael Dudley', 'age': 72, 'title': 'Co-Founder, CEO, President & Director', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 494000, 'exercisedValue': 0, 'unexercisedValue': 477391}, {'maxAge': 1, 'name': 'Mr. Thomas A. Fitzgerald M.B.A.', 'age': 71, 'title': 'CFO, VP of Administration & Director', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 371000, 'exercisedValue': 0, 'unexercisedValue': 143875}, {'maxAge': 1, 'name': 'Dr. Zdravka  Medarova Ph.D.', 'age': 48, 'title': 'Co-Founder & CTO', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Anna  Moore Ph.D.', 'age': 61, 'title': 'Co-Founder, Scientific Advisor & Member of Scientific Advisory Board', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan  Duggan M.B.A., R.N.', 'title': 'Senior Vice President of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Qiyong Peter Liu Ph.D.', 'age': 59, 'title': 'VP of Drug Discovery & Chief Scientist', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alan  Freidman', 'title': 'Vice President of Investor & Client Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.392
currency§USD
dateShortInterest§1702598400
forwardEps§-0.63
exchange§NCM
quoteType§EQUITY
shortName§TransCode Therapeutics, Inc.
longName§TransCode Therapeutics, Inc.
firstTradeDateEpochUtc§1625751000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§09a0c637-96b3-3583-b5c0-c18005c44a45
gmtOffSetMilliseconds§-18000000
targetHighPrice§3.0
targetLowPrice§3.0
targetMeanPrice§3.0
targetMedianPrice§3.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§1.331
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
